Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Yayi He; Yan Wang; Theresa Boyle; Shengxiang Ren; Dan Chan; Chris Rivard; Xuefei Li; Jiayu Li; Caicun Zhou; Fred R. Hirsch

doi:10.12659/MSM.896607

26 January 2016 : Clinical Research

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Yayi He^E, Yan Wang^B, Theresa Boyle^E, Shengxiang Ren^B, Dan Chan^C, Chris Rivard^F, Xuefei Li^F, Jiayu Li^E, Caicun Zhou^AG, Fred R. Hirsch^F

DOI: 10.12659/MSM.896607

Med Sci Monit 2016; 22:276-283

Authors information Article notes Copyright and License information

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Export

Export Article Citation

Export file: The selected type of file is required

Content:

Share via email

Share method:

Content:

Preview:

Your Privacy